PCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Regadenoson | PCS-499 may decrease effectiveness of Regadenoson as a diagnostic agent. |
| Adalimumab | The serum concentration of PCS-499 can be decreased when it is combined with Adalimumab. |
| Adenosine | The therapeutic efficacy of Adenosine can be decreased when used in combination with PCS-499. |
| Allopurinol | The serum concentration of PCS-499 can be increased when it is combined with Allopurinol. |
| Carbamazepine | The serum concentration of PCS-499 can be decreased when it is combined with Carbamazepine. |
| Cimetidine | The metabolism of PCS-499 can be decreased when combined with Cimetidine. |
| Disulfiram | The serum concentration of PCS-499 can be increased when it is combined with Disulfiram. |
| Febuxostat | The serum concentration of the active metabolites of PCS-499 can be increased when PCS-499 is used in combination with Febuxostat. |
| Fluvoxamine | The metabolism of PCS-499 can be decreased when combined with Fluvoxamine. |
| Formoterol | The risk or severity of hypokalemia can be increased when PCS-499 is combined with Formoterol. |
| Indacaterol | The risk or severity of adverse effects can be increased when PCS-499 is combined with Indacaterol. |
| Isoniazid | The serum concentration of PCS-499 can be increased when it is combined with Isoniazid. |
| Lithium citrate | The serum concentration of Lithium citrate can be decreased when it is combined with PCS-499. |
| Lithium carbonate | The serum concentration of Lithium carbonate can be decreased when it is combined with PCS-499. |
| Lithium hydroxide | The serum concentration of Lithium hydroxide can be decreased when it is combined with PCS-499. |
| Mexiletine | The metabolism of PCS-499 can be decreased when combined with Mexiletine. |
| Olodaterol | PCS-499 may increase the hyperkalemic activities of Olodaterol. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be decreased when used in combination with PCS-499. |
| Pentoxifylline | The serum concentration of PCS-499 can be increased when it is combined with Pentoxifylline. |
| Phenytoin | The serum concentration of PCS-499 can be decreased when it is combined with Phenytoin. |
| Fosphenytoin | The serum concentration of PCS-499 can be decreased when it is combined with Fosphenytoin. |
| Propafenone | The serum concentration of PCS-499 can be increased when it is combined with Propafenone. |
| Quinine | The serum concentration of PCS-499 can be increased when it is combined with Quinine. |
| Quinidine | The serum concentration of PCS-499 can be increased when it is combined with Quinidine. |
| Riociguat | PCS-499 may increase the hypotensive activities of Riociguat. |
| Thiabendazole | The metabolism of PCS-499 can be decreased when combined with Thiabendazole. |
| Ticlopidine | The metabolism of PCS-499 can be decreased when combined with Ticlopidine. |
| Zafirlukast | The serum concentration of Zafirlukast can be decreased when it is combined with PCS-499. |
| Probenecid | The serum concentration of PCS-499 can be increased when it is combined with Probenecid. |
| Isoprenaline | The serum concentration of PCS-499 can be decreased when it is combined with Isoprenaline. |
| Amphetamine | The risk or severity of adverse effects can be increased when Amphetamine is combined with PCS-499. |
| Phentermine | The risk or severity of adverse effects can be increased when Phentermine is combined with PCS-499. |
| Midodrine | The risk or severity of adverse effects can be increased when Midodrine is combined with PCS-499. |
| Norepinephrine | The risk or severity of adverse effects can be increased when Norepinephrine is combined with PCS-499. |
| Phenylephrine | The risk or severity of adverse effects can be increased when Phenylephrine is combined with PCS-499. |
| Phenylpropanolamine | The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with PCS-499. |
| Labetalol | The risk or severity of adverse effects can be increased when Labetalol is combined with PCS-499. |
| Metaraminol | The risk or severity of adverse effects can be increased when Metaraminol is combined with PCS-499. |
| Epinephrine | The risk or severity of adverse effects can be increased when Epinephrine is combined with PCS-499. |
| Methoxamine | The risk or severity of adverse effects can be increased when Methoxamine is combined with PCS-499. |
| Orciprenaline | The risk or severity of adverse effects can be increased when Orciprenaline is combined with PCS-499. |
| Phenmetrazine | The risk or severity of adverse effects can be increased when Phenmetrazine is combined with PCS-499. |
| Dobutamine | The risk or severity of adverse effects can be increased when Dobutamine is combined with PCS-499. |
| Pseudoephedrine | The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with PCS-499. |
| Benzphetamine | The risk or severity of adverse effects can be increased when Benzphetamine is combined with PCS-499. |
| Ritodrine | The risk or severity of adverse effects can be increased when Ritodrine is combined with PCS-499. |
| Terbutaline | The risk or severity of adverse effects can be increased when Terbutaline is combined with PCS-499. |
| Oxymetazoline | The risk or severity of adverse effects can be increased when Oxymetazoline is combined with PCS-499. |
| Diethylpropion | The risk or severity of adverse effects can be increased when Diethylpropion is combined with PCS-499. |
| Dopamine | The risk or severity of adverse effects can be increased when Dopamine is combined with PCS-499. |
| Acebutolol | The risk or severity of adverse effects can be increased when Acebutolol is combined with PCS-499. |
| Lisdexamfetamine | The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with PCS-499. |
| Fenoterol | The risk or severity of adverse effects can be increased when Fenoterol is combined with PCS-499. |
| Ephedrine | The risk or severity of adverse effects can be increased when Ephedrine is combined with PCS-499. |
| Mephentermine | The risk or severity of adverse effects can be increased when Mephentermine is combined with PCS-499. |
| Procaterol | The risk or severity of adverse effects can be increased when Procaterol is combined with PCS-499. |
| Clenbuterol | The risk or severity of adverse effects can be increased when Clenbuterol is combined with PCS-499. |
| MMDA | The risk or severity of adverse effects can be increased when MMDA is combined with PCS-499. |
| Midomafetamine | The risk or severity of adverse effects can be increased when Midomafetamine is combined with PCS-499. |
| 2,5-Dimethoxy-4-ethylamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with PCS-499. |
| 4-Bromo-2,5-dimethoxyamphetamine | The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with PCS-499. |
| Tenamfetamine | The risk or severity of adverse effects can be increased when Tenamfetamine is combined with PCS-499. |
| Chlorphentermine | The risk or severity of adverse effects can be increased when Chlorphentermine is combined with PCS-499. |
| Methylenedioxyethamphetamine | The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with PCS-499. |
| Dextroamphetamine | The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with PCS-499. |
| Metamfetamine | The risk or severity of adverse effects can be increased when Metamfetamine is combined with PCS-499. |
| Celiprolol | The risk or severity of adverse effects can be increased when Celiprolol is combined with PCS-499. |
| Nylidrin | The risk or severity of adverse effects can be increased when Nylidrin is combined with PCS-499. |
| Tetryzoline | The risk or severity of adverse effects can be increased when Tetryzoline is combined with PCS-499. |
| Tyramine | The risk or severity of adverse effects can be increased when Tyramine is combined with PCS-499. |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Isoxsuprine is combined with PCS-499. |
| Etilefrine | The risk or severity of adverse effects can be increased when Etilefrine is combined with PCS-499. |
| Synephrine | The risk or severity of adverse effects can be increased when Synephrine is combined with PCS-499. |
| Hydroxyamphetamine | The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with PCS-499. |
| Iofetamine I-123 | The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with PCS-499. |
| Racepinephrine | The risk or severity of adverse effects can be increased when Racepinephrine is combined with PCS-499. |
| Ritobegron | The risk or severity of adverse effects can be increased when Ritobegron is combined with PCS-499. |
| Bucindolol | The risk or severity of adverse effects can be increased when Bucindolol is combined with PCS-499. |
| Tramazoline | The risk or severity of adverse effects can be increased when Tramazoline is combined with PCS-499. |
| Mephedrone | The risk or severity of adverse effects can be increased when Mephedrone is combined with PCS-499. |
| Fenozolone | The risk or severity of adverse effects can be increased when Fenozolone is combined with PCS-499. |
| Methoxyphenamine | The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with PCS-499. |
| Tretoquinol | The risk or severity of adverse effects can be increased when Tretoquinol is combined with PCS-499. |
| Gepefrine | The risk or severity of adverse effects can be increased when Gepefrine is combined with PCS-499. |
| Epanolol | The risk or severity of adverse effects can be increased when Epanolol is combined with PCS-499. |
| Prenalterol | The risk or severity of adverse effects can be increased when Prenalterol is combined with PCS-499. |
| Mefenorex | The risk or severity of adverse effects can be increased when Mefenorex is combined with PCS-499. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with PCS-499. |
| Timolol | The risk or severity of adverse effects can be increased when Timolol is combined with PCS-499. |
| Sotalol | The risk or severity of adverse effects can be increased when Sotalol is combined with PCS-499. |
| Propranolol | The risk or severity of adverse effects can be increased when Propranolol is combined with PCS-499. |
| Alprenolol | The risk or severity of adverse effects can be increased when Alprenolol is combined with PCS-499. |
| Pindolol | The risk or severity of adverse effects can be increased when Pindolol is combined with PCS-499. |
| Carvedilol | The risk or severity of adverse effects can be increased when Carvedilol is combined with PCS-499. |
| Bevantolol | The risk or severity of adverse effects can be increased when Bevantolol is combined with PCS-499. |
| Practolol | The risk or severity of adverse effects can be increased when Practolol is combined with PCS-499. |
| Penbutolol | The risk or severity of adverse effects can be increased when Penbutolol is combined with PCS-499. |
| Oxprenolol | The risk or severity of adverse effects can be increased when Oxprenolol is combined with PCS-499. |
| Dexpropranolol | The risk or severity of adverse effects can be increased when Dexpropranolol is combined with PCS-499. |
| Bufuralol | The risk or severity of adverse effects can be increased when Bufuralol is combined with PCS-499. |